Analyses / UNH
Large-cap managed care after a 10.2% one-day drop. Revenue still growing, earnings shrinking, and the payload does not explain the move.
A free account reveals UNH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Revenue growth of 11.35% (5Y: 11.72%) and a P/S of 0.76 leave room for a rebound if the selloff proves sentiment-driven. Insider activity is net buying: 111 buys vs 30 sells, 217,674 shares bought vs 64,377 sold. Trailing P/E of 21.5 is below the forward P/E of 28.3, which could point to a reset. Price sits 24% below the 52-week high of 461.62. Beta of 0.50 is low.
▼ Bear Case
EPS growth is -14.51% (5Y: -3.76%), and forward P/E of 28.3 implies lower expected earnings. Net margin of 2.69% and operating margin of 4.18% leave little cushion. Current ratio 0.89 and quick ratio 0.67 are below 1.0. The session low of 342.46 was far below the prior close of 389.68, so the selling pressure is not yet explained. Payout ratio of 65.66% limits flexibility.
Valuation
MIXED — score 50/100
Low sales multiple and insider buying offset high forward P/E and negative EPS growth. No clear valuation edge in the payload.
Technical Levels
Support · $342.46 (Session low (intraday)) · $255.97 (52-week low)
Resistance · $387.53 (Session high (intraday)) · $389.68 (Prior close) · $461.62 (52-week high)
RSI: Unavailable in payload
Financial Health
Score 45/100. Thin margins and sub-1.0 liquidity ratios are the main concerns. Debt-to-equity is not in payload, so leverage cannot be fully assessed.
Catalysts
| Cause of the -10.2% session drop (not identified in payload) | Unknown | high |
| Next company earnings report (date not in payload) | Unknown | high |
| Managed-care policy and reimbursement headlines (general sector factor, no payload detail) | Ongoing | medium |
Risk Flags
See UNH's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock UNH free →Recent News
- Dow Jones Futures Rise, Techs Jump 2%: Anthropic To Debut After Strong IPO; Palo Alto, Everpure Rally On EarningsYahoo
- Is Cigna Stock A Real Bargain?Yahoo
- Should I Buy Humana Stock Now?Yahoo
- What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 17Yahoo
- Should You Buy UnitedHealth Group Stock For Its Cash?Yahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full UNH analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
UNH FAQ
Is UNH a buy right now?
UnitedHealth Group Incorporated's current read is a Recovery / value, unresolved setup with low confidence over a 1-3 months horizon. Valuation: MIXED. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is UNH overvalued?
MIXED (valuation score 50/100). Low sales multiple and insider buying offset high forward P/E and negative EPS growth. No clear valuation edge in the payload.
What are the risks of buying UNH?
EPS growth is -14.51% (5Y: -3.76%), and forward P/E of 28.3 implies lower expected earnings. Net margin of 2.69% and operating margin of 4.18% leave little cushion. Current ratio 0.89 and quick ratio 0.67 are below 1.0. The session low of 342.46 was far below the prior close of 389.68, so the selling pressure is not yet explained. Payout ratio of 65.66% limits flexibility.